Literature DB >> 35288829

Association Between Ex Vivo Human Ulcerative Colitis Explant Protein Secretion Profiles and Disease Behaviour.

R M Corcoran1,2, P MacDonagh1,2, F O'Connell2,3, M E Morrissey2,3, M R Dunne2,3, R Argue1, J O'Sullivan2,3, D Kevans4,5,6.   

Abstract

BACKGROUND: The clinical course of ulcerative colitis (UC) is variable. There is an unmet clinical need for biomarkers of UC disease behaviour. We aimed to evaluate the association between ex vivo human UC explant conditioned media (explant-CM) secreted protein profiles and UC disease behaviour.
METHODS: UC patients undergoing endoscopy were prospectively recruited. Endoscopic biopsies were collected and explant-CM generated. Association between explant-CM protein secretion profiles and disease progression was evaluated. Disease progression was defined as the requirement for corticosteroid therapy, UC-related hospitalisation, UC-related surgery or the introduction of a new immunomodulatory agent. Association between explant-CM secreted protein profiles and anti-TNF failure status was also evaluated. p values < 0.05 were considered significant in analyses.
RESULTS: Twenty-four UC patients were included (age [median, range]) 55 [21-72] years; 50% female. Disease progression during follow-up occurred in twelve (50%) patients. Multivariate analysis, including endoscopic remission status, demonstrated reduced IL-2 secretion to be independently associated with UC disease progression, p = 0.01. In univariate analysis, anti-TNF failure status was associated with significantly increased IL-17A/F (p = 0.015) and IL-12 / IL-23p40 (p = 0.044) concentrations. In multivariate analysis, there was a trend towards an association between IL-17A/F and anti-TNF failure status (p = 0.069); FLT-1 was demonstrated to be independently associated with anti-TNF failure status (p = 0.016).
CONCLUSION: Reduced explant-CM secreted IL-2 is associated with UC disease progression. Increased secretion of IL-23 pathway-associated cytokines was observed in anti-TNF failure status consistent with previous reports. Ex vivo human UC explants, generated from endoscopic biopsies, have potential as precision medicine tools in inflammatory bowel disease.
© 2022. The Author(s).

Entities:  

Keywords:  Disease behaviour; Secreted proteins; UC explant

Year:  2022        PMID: 35288829     DOI: 10.1007/s10620-022-07411-0

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  37 in total

1.  Risk factors and characteristics of extent progression in ulcerative colitis.

Authors:  María Josefina Etchevers; Montserrat Aceituno; Orlando García-Bosch; Ingrid Ordás; Miquel Sans; Elena Ricart; Julián Panés
Journal:  Inflamm Bowel Dis       Date:  2009-09       Impact factor: 5.325

2.  Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis.

Authors:  Jean Frédéric Colombel; Paul Rutgeerts; Walter Reinisch; Dirk Esser; Yanxin Wang; Yinghua Lang; Colleen W Marano; Richard Strauss; Björn J Oddens; Brian G Feagan; Stephen B Hanauer; Gary R Lichtenstein; Daniel Present; Bruce E Sands; William J Sandborn
Journal:  Gastroenterology       Date:  2011-06-30       Impact factor: 22.682

3.  Increased expression of interleukin 17 in inflammatory bowel disease.

Authors:  S Fujino; A Andoh; S Bamba; A Ogawa; K Hata; Y Araki; T Bamba; Y Fujiyama
Journal:  Gut       Date:  2003-01       Impact factor: 23.059

Review 4.  Prognosis in ulcerative colitis.

Authors:  O Broström
Journal:  Med Clin North Am       Date:  1990-01       Impact factor: 5.456

5.  Colorectal cancer risk and mortality in patients with ulcerative colitis.

Authors:  E Langholz; P Munkholm; M Davidsen; V Binder
Journal:  Gastroenterology       Date:  1992-11       Impact factor: 22.682

Review 6.  Ulcerative colitis.

Authors:  Taku Kobayashi; Britta Siegmund; Catherine Le Berre; Shu Chen Wei; Marc Ferrante; Bo Shen; Charles N Bernstein; Silvio Danese; Laurent Peyrin-Biroulet; Toshifumi Hibi
Journal:  Nat Rev Dis Primers       Date:  2020-09-10       Impact factor: 52.329

7.  Preclinical validation of the small molecule drug quininib as a novel therapeutic for colorectal cancer.

Authors:  Adrian G Murphy; Rory Casey; Aoife Maguire; Miriam Tosetto; Clare T Butler; Emer Conroy; Alison L Reynolds; Kieran Sheahan; Diarmuid O'Donoghue; William M Gallagher; David Fennelly; Breandán N Kennedy; Jacintha O'Sullivan
Journal:  Sci Rep       Date:  2016-10-14       Impact factor: 4.379

8.  Serum interleukin 17A and interleukin 17F in children with inflammatory bowel disease.

Authors:  Paulina Krawiec; Elżbieta Pac-Kożuchowska
Journal:  Sci Rep       Date:  2020-07-28       Impact factor: 4.379

9.  Outcomes and Strategies to Support a Treat-to-target Approach in Inflammatory Bowel Disease: A Systematic Review.

Authors:  Jean-Frédéric Colombel; Geert D'haens; Wan-Ju Lee; Joel Petersson; Remo Panaccione
Journal:  J Crohns Colitis       Date:  2020-02-10       Impact factor: 9.071

Review 10.  Patient-derived explants (PDEs) as a powerful preclinical platform for anti-cancer drug and biomarker discovery.

Authors:  Ian R Powley; Meeta Patel; Gareth Miles; Howard Pringle; Lynne Howells; Anne Thomas; Catherine Kettleborough; Justin Bryans; Tim Hammonds; Marion MacFarlane; Catrin Pritchard
Journal:  Br J Cancer       Date:  2020-01-02       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.